Menu
GWAS Study

Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications.

Wolking S, Campbell C, Stapleton C et al.

34177598 PubMed ID
GWAS Study Type
936 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

WS
Wolking S
CC
Campbell C
SC
Stapleton C
MM
McCormack M
DN
Delanty N
DC
Depondt C
JM
Johnson MR
KB
Koeleman BPC
KR
Krause R
KW
Kunz WS
MA
Marson AG
SJ
Sander JW
SG
Sills GJ
SP
Striano P
ZF
Zara F
SS
Sisodiya SM
CG
Cavalleri GL
LH
Lerche H
Chapter II

Abstract

Summary of the research findings

Objective: Resistance to anti-seizure medications (ASMs) presents a significant hurdle in the treatment of people with epilepsy. Genetic markers for resistance to individual ASMs could support clinicians to make better-informed choices for their patients. In this study, we aimed to elucidate whether the response to individual ASMs was associated with common genetic variation. Methods: A cohort of 3,649 individuals of European descent with epilepsy was deeply phenotyped and underwent single nucleotide polymorphism (SNP)-genotyping. We conducted genome-wide association analyses (GWASs) on responders to specific ASMs or groups of functionally related ASMs, using non-responders as controls. We performed a polygenic risk score (PRS) analyses based on risk variants for epilepsy and neuropsychiatric disorders and ASM resistance itself to delineate the polygenic burden of ASM-specific drug resistance. Results: We identified several potential regions of interest but did not detect genome-wide significant loci for ASM-specific response. We did not find polygenic risk for epilepsy, neuropsychiatric disorders, and drug-resistance associated with drug response to specific ASMs or mechanistically related groups of ASMs. Significance: This study could not ascertain the predictive value of common genetic variants for ASM responder status. The identified suggestive loci will need replication in future studies of a larger scale.

258 European ancestry cases, 678 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

936
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.